Recombinant adeno-associated viruses (rAAV2) facilitate the intraperitoneal gene delivery to cancer cells

Malecki,Maciej; Proczka,Robert; Chorostowska-Wynimko,Joanna; Swoboda,Pawe&#322;; Delbani,Anna; Pachecka,Jan

doi:10.3892/ol_00000032

January-February 2010 Volume 1 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-February 2010 Volume 1 Issue 1

Full Size Image

Article

Recombinant adeno-associated viruses (rAAV2) facilitate the intraperitoneal gene delivery to cancer cells

Authors:
- Maciej Malecki
- Robert Proczka
- Joanna Chorostowska-Wynimko
- Paweł Swoboda
- Anna Delbani
- Jan Pachecka
View Affiliations / Copyright

Affiliations: Department of Cell Biology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Medical University of Warsaw, Warsaw, Poland
Pages: 177-180
|
Published online on: January 1, 2010

https://doi.org/10.3892/ol_00000032
Expand metrics +

Abstract

Peritoneal dissemination of cancer cells is characteristic of advanced stages of ovarian, breast and lung cancers, and is associated with poor patient survival. The presence of cancer cells in effusions complicates treatment protocols, while cell eradication is seriously limited. One of the novel options available is cancer gene therapy with recombinant adeno-associated viruses. This combination represents the most promising gene delivery vehicles to neoplasmatic cells within serosal cavities due to their unique properties that include the ability to infect proliferating cells of broad host range, as well as the potential of long-term expression. Recombinant infectious adeno-associated virus serotype 2 particles (rAAV2) were produced in a helper-free system using an AAV-293 packaging cell line, and quantitatively analyzed by real-time PCR. Balb/c mice intraperitoneally pre-injected with L1 cancer cells were treated with different doses of rAAV2. Subsequently, the mice were sacrificed and intraperitoneal effusions were analyzed for rAAV presence and rAAV/β-galactosidase (LacZ) vector efficiency in order to infect cancer cells within the peritoneal cavity. We reported an efficient infection of L1 cancer cells disseminated into the peritoneal cavity by rAAV2. The expression of reporter genes (GFP and LacZ) attributable to the rAAV cell uptake was closely dependent on an applied multiplicity of infection ratio (MOI). The highest infection efficiency was observed at a MOI of 50 and 200. Our study confirmed the ability of adeno-associated viruses to facilitate gene transferability to cancer cells disseminated in the serosal cavity, as well as the potential usefulness of these viruses as a new approach in cancer gene therapy.

View Figures

View References

1	Reibenwein J and Krainer M: Targeting signaling pathways in ovarian cancer. Expert Opin Ther Targets. 12:353–365. 2008. View Article : Google Scholar : PubMed/NCBI
2	Cannistra SA: Cancer of ovary. N Engl J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
3	Blaese RM, Culver KW, Miller AD, et al: T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 270:475–480. 1995.PubMed/NCBI
4	www.wiley.co.uk
5	Porteus MH, Connelly JP and Pruett SM: A look to future directions in gene therapy research for monogenic diseases. PLoS Genet. 2:1285–1292. 2006. View Article : Google Scholar : PubMed/NCBI
6	Raty JK, Lesch HP, Wirth T and Ylä-Herttuala S: Improving safety of gene therapy. Curr Drug Saf. 3:46–53. 2008. View Article : Google Scholar
7	Le Bec C and Douar A: Gene therapy progress and prospects-vectorology: design and production of expression cassettes in AAV vectors. Gene Ther. 13:805–813. 2006.PubMed/NCBI
8	Atchison RW, Casto BC and Hammon WM: Adenovirus-associated defective virus particles. Science. 149:754–756. 1965. View Article : Google Scholar : PubMed/NCBI
9	Małecki M, WoŸniak A and Janik P: Wirusy związane z adenowirusami (AAV). Postępy Biochem. 54:57–63. 2008.
10	Flotte TR: Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 11:805–810. 2004. View Article : Google Scholar : PubMed/NCBI
11	Isayeva T, Ren C and Ponnazhagan S: Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer. Clin Cancer Res. 11:1342–1347. 2005.
12	Isayeva T, Ren C and Ponnazhagan S: Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway. Gene Ther. 14:138–146. 2007.PubMed/NCBI
13	Li J, Zhou J, Chen G, et al: Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model. Cancer Gene Ther. 13:266–272. 2006. View Article : Google Scholar : PubMed/NCBI
14	Zolotukhin S, Byrne BJ, Mason E, et al: Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6:973–985. 1999. View Article : Google Scholar : PubMed/NCBI
15	Davidson B: Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog. 13:189–227. 2007. View Article : Google Scholar : PubMed/NCBI
16	Malecki M, Kolsut P and Proczka P: Angiogenic and antiangiogenic gene therapy. Gene Ther. 12:159–169. 2005. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Recombinant adeno-associated viruses (rAAV2) facilitate the intraperitoneal gene delivery to cancer cells

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles